ALXO
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Nature Medicine publishes Phase 2 ASPEN-06 data showing strong responses and durable clinical benefit with evorpacept in HER2-positive gastric cancerSep 28, 2026
- ALX Oncology reports durable responses from evorpacept combination in advanced HER2-positive breast cancerMay 7, 2026
- New data showed CD47 expression predicts response to evorpacept plus zanidatamab in breast cancerJan 30, 2026
- ALX Oncology advanced separate clinical trials for evorpacept and ALX2004Jan 8, 2026
- ALX Oncology announces preclinical data and Phase 1 trial-in-progress presentations of ALX2004, a novel EGFR-targeted ADC, at 2025 AACR-NCI-EORTC ConferenceOct 24, 2025